Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Gains from Sales and Divestitures (2023 - 2026)

Prelude Therapeutics' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $59557.0 for Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures rose 535.27% to $59557.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $59557.0, a 535.27% increase, with the full-year FY2025 number at $37500.0, down 11.76% from a year prior.
  • Gains from Sales and Divestitures hit $59557.0 in Q1 2026 for Prelude Therapeutics, up from $37500.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for PRLD hit a ceiling of $61250.0 in Q4 2023 and a floor of $9375.0 in Q1 2025.
  • Historically, Gains from Sales and Divestitures has averaged $32169.8 across 4 years, with a median of $27566.5 in 2024.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 30.61% in 2024 and later skyrocketed 535.27% in 2026.
  • Tracing PRLD's Gains from Sales and Divestitures over 4 years: stood at $61250.0 in 2023, then plummeted by 30.61% to $42500.0 in 2024, then fell by 11.76% to $37500.0 in 2025, then surged by 58.82% to $59557.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for PRLD at $59557.0 in Q1 2026, $37500.0 in Q4 2025, and $28125.0 in Q3 2025.